AOD-9604 FDA and compounding status (2026)

The short answer. AOD-9604 is not FDA-approved and, as of September 26, 2026, has no compounding pathway. FDA’s advisory committee voted 0 to 12 against listing it on December 4, 2024. The “GRAS” claim on vendor pages is not an FDA determination: FDA said on the record that AOD-9604 is not on its GRAS list.

FDA approved No. Its developer ended obesity development in 2007 after a Phase 2b trial.
503A pharmacy No pathway. Not on 21 CFR 216.23 and in no category since Sep 27, 2024.
503B outsourcing facility No pathway.
Latest FDA action Advisory committee, Dec 4, 2024: 0-12 against listing.
Sport and military WADA prohibited (S2.2.3, growth hormone fragments). DoD prohibited dietary supplement ingredient.
MDside position Our providers do not prescribe it.
Last verified 2026-09-26

The GRAS claim does not hold

Vendors often describe AOD-9604 as “GRAS,” generally recognized as safe. At the December 2024 committee meeting, FDA staff stated on the record that AOD-9604 is not on FDA’s GRAS list and has not been through FDA’s GRAS process, and that the company’s claim was its own self-determination. A GRAS position, even a valid one, covers use in food. It says nothing about an injection.

The drug program ended in 2007

AOD-9604 is a synthetic fragment of human growth hormone. FDA’s briefing records that its developer, Metabolic Pharmaceuticals, announced on February 21, 2007 that Phase 2b results did not support it as a treatment for obesity and ended development for that use. No approved drug followed.

The compounding record

Both nominators withdrew in September 2024, which took AOD-9604 out of Category 2. FDA reviewed it at the December 4, 2024 committee meeting regardless, and the committee voted 0 to 12 against listing it, matching FDA’s recommendation. FDA’s safety-risk page cites a possible immunogenicity risk and serious adverse events of unclear cause. FDA’s 2022 warning letter to Innoveix cited a recall of compounded AOD-9604 for lack of sterility assurance.

What this means for you

Take AOD-9604 off your menu, in injectable and oral forms. Remove any page that calls it GRAS or FDA-cleared. If a patient wants a weight program, the conversation belongs with the approved options: see our weight management program and the semaglutide page.

Read next

Frequently asked questions

Is AOD-9604 legal to compound?

No. As of September 26, 2026 AOD-9604 is not on the 503A bulks list, sits in no FDA category, has no monograph and is not part of an approved drug. FDA’s advisory committee voted 0 to 12 against listing it in December 2024, and no rule has followed.

Is AOD-9604 GRAS?

Not by any FDA determination. At the December 2024 committee meeting FDA staff stated that AOD-9604 is not on FDA’s GRAS list and has not been through FDA’s GRAS process, and described the company’s claim as a self-determination. A GRAS position also covers food use only and never an injection.

Is AOD-9604 banned in sports?

Yes. The 2026 WADA Prohibited List names AOD-9604 under S2.2.3 as a growth hormone fragment, prohibited at all times. The Department of Defense also lists it as a prohibited dietary supplement ingredient. Clinics serving athletes or service members carry that exposure on top of the compounding problem.


Primary sources. Last verified September 26, 2026. Corrections are welcome: contact us.

This is general information, not legal advice. Rules vary by state and change. Confirm your own facts with counsel.

Reviewed by Gavin W. Sigle, MD, colon and rectal surgery, Tampa, Florida. Last reviewed 2026-09-26.